We will use cookies and other information to optimize your experience. By continuing to browse, you consent to our use. For details, please read Privacy Policy
Gongwin Biopharm Co., Ltd.
Language
  • 繁體中文
  • English
  • About Us
    • Company Profile
    • History
    • Our Team
    • Partnership
  • News&Media
    • Press Release
    • Recent Activity
    • Events
  • Pipeline
  • Products
    • PTS302 NSCLC-SMAO
    • PTS100 HCC
    • PTS-02 ACC
    • PTS500 MPE
  • R & D
    • Core Technology
    • Mechanism of Action
    • R & D Center
    • Patent Portfolio
    • Published Paper
  • Investors
    • Financial information
      • Company annual report
      • Financial report
      • Monthly revenue
      • Legal person briefing
    • Corporate Governance
      • Corporate governance structure
      • Board of Directors
      • Committee
      • Internal audit
      • Company regulations
      • Other corporate governance information
    • Shareholder area
      • Shareholders' meeting
      • Dividend distribution
      • Material message
      • Stock price message
      • Investor Relations Contact Window
      • Stock agency
    • Interest relationship
      • Interested parties communicate with the company
  • Join Us
  • Contact
  1. Home
  2. News&Media
DOMINOInterior Design
News&Media
  • Press Release
  • Recent Activity
  • Events
Press Release
  • 052018.11
    2018-11-05 Gongwin-KY cancer new drug PT...
    Accepted by the internationally renowned journal Frontiers in Pharmacology.....Read More
  • 112018.10
    2018-10-11 China Drug Certification Revi...
    PTS302 is Worthy of Attention and Optimistic Market Prospects are anticipated.....Read Mo...
  • 082018.08
    2018-08-08 KY liver cancer new drug PTS1...
    KY liver cancer new drug PTS100 clinically locked liver cancer patients accelerated phase ...
  • 252018.06
    2018-06-25 Taking advantage of China CFD...
    Taking advantage of China CFDA priority approval policy.....Read More
  • 022018.05
    2018-05-02 KY completed 297 million yuan...
    KY completed 297 million yuan in cash increase the net value.....Read More
  • 282018.02
    2018-02-28 Gongwin-KY to Co-Operate with...
    KY liver cancer new drug PTS100 and Taiwan University Hospital.....Read More
  • 1
  • 2
CONTACTS
  • Gongwin Biopharm Holdings Co., Ltd.
  • 02-2503-5282
  • E-mail info@gongwinbiopharm.com
  • Address 3F., No.80, Sec. 1, Jianguo N. Rd., Zhongshan Dist., Taipei City 104, Taiwan (R.O.C.)
NAVIGATION
  • About Us
  • News&Media
  • Pipeline
  • Products
  • R & D
  • Investors
  • Join Us
  • Contact
  • Terms
  • Disclaimer

Copyright © Gongwin Biopharm Holdings Co., Ltd. All Rights Reserved. Web design : DOMINO

  • 繁體中文
  • English
Language
  • 繁體中文
  • English
  • About Us
    • Company Profile
    • History
    • Our Team
    • Partnership
  • News&Media
    • Press Release
    • Recent Activity
    • Events
  • Pipeline
  • Products
    • PTS302 NSCLC-SMAO
    • PTS100 HCC
    • PTS-02 ACC
    • PTS500 MPE
  • R & D
    • Core Technology
    • Mechanism of Action
    • R & D Center
    • Patent Portfolio
    • Published Paper
  • Investors
    • Financial information
      • Company annual report
      • Financial report
      • Monthly revenue
      • Legal person briefing
    • Corporate Governance
      • Corporate governance structure
      • Board of Directors
      • Committee
      • Internal audit
      • Company regulations
      • Other corporate governance information
    • Shareholder area
      • Shareholders' meeting
      • Dividend distribution
      • Material message
      • Stock price message
      • Investor Relations Contact Window
      • Stock agency
    • Interest relationship
      • Interested parties communicate with the company
  • Join Us
  • Contact